Effects of the peripheral CB1 receptor antagonist JD5037 in mono- and polytherapy with the AMPK activator metformin in a monocrotaline-induced rat model of pulmonary hypertension

Pulmonary hypertension (PH) is a disease leading to increased pressure in the pulmonary artery and right heart failure. The adenosine monophosphate-activated protein kinase (AMPK) activator, metformin, has a protective effect against PH. CB1 receptor blockade reduces the number of pathological alter...

Full description

Saved in:
Bibliographic Details
Main Authors: Patryk Remiszewski (Author), Anna Pędzińska-Betiuk (Author), Krzysztof Mińczuk (Author), Eberhard Schlicker (Author), Justyna Klimek (Author), Janusz Dzięcioł (Author), Barbara Malinowska (Author)
Format: Book
Published: Frontiers Media S.A., 2022-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8c70a34cdf564994aea7e6b801aed5a9
042 |a dc 
100 1 0 |a Patryk Remiszewski  |e author 
700 1 0 |a Anna Pędzińska-Betiuk  |e author 
700 1 0 |a Krzysztof Mińczuk  |e author 
700 1 0 |a Eberhard Schlicker  |e author 
700 1 0 |a Justyna Klimek  |e author 
700 1 0 |a Janusz Dzięcioł  |e author 
700 1 0 |a Barbara Malinowska  |e author 
245 0 0 |a Effects of the peripheral CB1 receptor antagonist JD5037 in mono- and polytherapy with the AMPK activator metformin in a monocrotaline-induced rat model of pulmonary hypertension 
260 |b Frontiers Media S.A.,   |c 2022-09-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2022.965613 
520 |a Pulmonary hypertension (PH) is a disease leading to increased pressure in the pulmonary artery and right heart failure. The adenosine monophosphate-activated protein kinase (AMPK) activator, metformin, has a protective effect against PH. CB1 receptor blockade reduces the number of pathological alterations in experimental lung fibrosis. The current study evaluates the effect of the peripheral cannabinoid CB1 receptor antagonist JD5037 in mono- and polytherapy with metformin in rat monocrotaline-induced mild PH. Animals received metformin (100 mg/kg), JD5037 (3 mg/kg), or a combination of both once daily for 21 days. Monocrotaline (60 mg/kg) increased right ventricular (RV) systolic pressure (RVSP), led to RV and lung hypertrophy and remodeling, and decreased oxygen saturation. Metformin partially restored the monocrotaline-induced effects, i.e., decreased RVSP, increased oxygen saturation, and counteracted cardiac fibrotic, hypertrophic, and inflammatory changes. JD5037 modified parameters related to inflammation and/or fibrosis. Only polytherapy with metformin and JD5037 improved Fulton's index and coronary artery hypertrophy and tended to be more effective than monotherapy against alterations in RVSP, oxygen saturation and coronary artery tunica media vacuolization. In conclusion, monotherapy with JD5037 does not markedly influence the PH-related changes. However, polytherapy with metformin tends to be more efficient than any of these compounds alone. 
546 |a EN 
690 |a AMP-activated protein kinase 
690 |a cannabinoid 1 receptor 
690 |a JD5037 
690 |a metformin 
690 |a monocrotaline 
690 |a polytherapy 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 13 (2022) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2022.965613/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/8c70a34cdf564994aea7e6b801aed5a9  |z Connect to this object online.